MedTrace Logo

Screening for High Frequency Malignant Disease

NCT05117840 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 12000

Last updated 2026-07-06

No results posted yet for this study

Summary

The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

Conditions

Interventions

DEVICE

Low-dose CT scan

Standard of care screening for individuals at high-risk of lung cancer

Sponsors & Collaborators

  • Guardant Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Hannah Oakley · Guardant Health, Inc.

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117840 on ClinicalTrials.gov